EPS for Calavo Growers, Inc. (CVGW) Expected At $0.41; Eleven Biotherapeutics (EBIO) Shorts Raised By 27.45%

December 8, 2017 - By Louis Casey

Analysts expect Calavo Growers, Inc. (NASDAQ:CVGW) to report $0.41 EPS on December, 19.They anticipate $0.12 EPS change or 22.64% from last quarter’s $0.53 EPS. CVGW’s profit would be $7.19M giving it 44.15 P/E if the $0.41 EPS is correct. After having $0.50 EPS previously, Calavo Growers, Inc.’s analysts see -18.00% EPS growth. The stock decreased 2.16% or $1.6 during the last trading session, reaching $72.4. About 123,614 shares traded or 21.74% up from the average. Calavo Growers, Inc. (NASDAQ:CVGW) has risen 17.64% since December 8, 2016 and is uptrending. It has outperformed by 0.94% the S&P500.

Eleven Biotherapeutics Incorporated (NASDAQ:EBIO) had an increase of 27.45% in short interest. EBIO’s SI was 1.76M shares in December as released by FINRA. Its up 27.45% from 1.38 million shares previously. With 302,300 avg volume, 6 days are for Eleven Biotherapeutics Incorporated (NASDAQ:EBIO)’s short sellers to cover EBIO’s short positions. The SI to Eleven Biotherapeutics Incorporated’s float is 20.21%. The stock increased 4.90% or $0.0317 during the last trading session, reaching $0.6788. About 1.92 million shares traded or 108.78% up from the average. Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) has risen 30.97% since December 8, 2016 and is uptrending. It has outperformed by 14.27% the S&P500.

Calavo Growers, Inc. markets and distributes avocados, prepared avocados, and other perishable foods to food distributors, produce wholesalers, supermarkets, convenience stores, and restaurants worldwide. The company has market cap of $1.27 billion. It operates in three divisions: Fresh Products, Calavo Foods, and RFG. It has a 34.98 P/E ratio. The Fresh products segment distributes avocados and other fresh produce products; and procures avocados grown in Mexico, as well as various other commodities, including tomatoes, papayas, and pineapples.

Among 5 analysts covering Calavo Growers (NASDAQ:CVGW), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Calavo Growers had 16 analyst reports since August 24, 2015 according to SRatingsIntel. The rating was maintained by Lake Street with “Buy” on Wednesday, December 21. As per Thursday, December 15, the company rating was upgraded by DA Davidson. The stock of Calavo Growers, Inc. (NASDAQ:CVGW) has “Buy” rating given on Friday, January 15 by Buckingham Research. DA Davidson downgraded the stock to “” rating in Wednesday, March 2 report. Lake Street maintained it with “Buy” rating and $71 target in Thursday, September 8 report. Lake Street maintained Calavo Growers, Inc. (NASDAQ:CVGW) rating on Wednesday, December 30. Lake Street has “Buy” rating and $59.0 target. The stock of Calavo Growers, Inc. (NASDAQ:CVGW) has “Neutral” rating given on Friday, September 4 by DA Davidson. DA Davidson upgraded the shares of CVGW in report on Thursday, January 7 to “Buy” rating. On Friday, September 4 the stock rating was upgraded by BB&T Capital to “Buy”. The company was initiated on Monday, October 19 by Buckingham Research.

Investors sentiment increased to 1.88 in Q2 2017. Its up 0.31, from 1.57 in 2017Q1. It increased, as 15 investors sold Calavo Growers, Inc. shares while 42 reduced holdings. 37 funds opened positions while 70 raised stakes. 14.61 million shares or 5.57% more from 13.84 million shares in 2017Q1 were reported. Moreover, Rhumbline Advisers has 0% invested in Calavo Growers, Inc. (NASDAQ:CVGW) for 29,938 shares. Ls Advisors Ltd Liability Co has 1,476 shares. Prudential Fincl Inc, New Jersey-based fund reported 26,576 shares. Creative Planning has 0% invested in Calavo Growers, Inc. (NASDAQ:CVGW). Federated Invsts Inc Pa reported 0% stake. Legal And General Public owns 0% invested in Calavo Growers, Inc. (NASDAQ:CVGW) for 27,904 shares. Voya Inv Lc reported 7,590 shares stake. Ranger Inv Mngmt Limited Partnership has 551,377 shares for 2.71% of their portfolio. White Pine Cap Llc invested in 31,085 shares. Neuberger Berman Lc invested 0.13% in Calavo Growers, Inc. (NASDAQ:CVGW). California-based First Republic Inv Management has invested 0% in Calavo Growers, Inc. (NASDAQ:CVGW). Retail Bank Of Mellon holds 0.01% of its portfolio in Calavo Growers, Inc. (NASDAQ:CVGW) for 380,669 shares. The California-based L & S Advsr Incorporated has invested 0.05% in Calavo Growers, Inc. (NASDAQ:CVGW). State Board Of Administration Of Florida Retirement System has 0% invested in Calavo Growers, Inc. (NASDAQ:CVGW) for 9,944 shares. Huntington Fincl Bank, Ohio-based fund reported 339 shares.

Since June 13, 2017, it had 0 insider purchases, and 1 insider sale for $56,324 activity. 750 shares valued at $56,324 were sold by Brown Marc Laurence on Tuesday, June 13.

Eleven Biotherapeutics, Inc., a biologic oncology company, focuses on the design and development of targeted protein therapeutics . The company has market cap of $21.61 million. It develops products based on its proprietary TPT platform and focused on addressing areas of unmet medical needs in cancer. It currently has negative earnings. The companyÂ’s lead product candidates include Vicinium that is in Phase 3 clinical trial in the United States and Canada for the treatment of non-muscle invasive bladder cancer; and Proxinium for use in treating squamous cell carcinoma of the head and neck.

Among 2 analysts covering Eleven Biotherapeutics (NASDAQ:EBIO), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. Eleven Biotherapeutics has $8.35 highest and $0.40 lowest target. $4.38’s average target is 545.26% above currents $0.6788 stock price. Eleven Biotherapeutics had 4 analyst reports since August 15, 2015 according to SRatingsIntel. Citigroup maintained it with “Neutral” rating and $0.40 target in Wednesday, March 16 report. The rating was downgraded by Citigroup on Tuesday, January 19 to “Neutral”. Leerink Swann downgraded Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) on Tuesday, January 19 to “Market Perform” rating. The stock of Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) has “Outperform” rating given on Saturday, August 15 by Leerink Swann.

Investors sentiment decreased to 1.83 in 2017 Q2. Its down 0.05, from 1.88 in 2017Q1. It turned negative, as 4 investors sold Eleven Biotherapeutics, Inc. shares while 2 reduced holdings. 6 funds opened positions while 5 raised stakes. 1.23 million shares or 17.39% more from 1.05 million shares in 2017Q1 were reported. Art Advisors Ltd Liability Co invested in 0% or 49,643 shares. Fincl Bank Of Montreal Can reported 5,000 shares. Citigroup reported 500 shares. 445,404 were accumulated by Blackrock Incorporated. Spark Investment Limited Company stated it has 0.01% of its portfolio in Eleven Biotherapeutics, Inc. (NASDAQ:EBIO). Morgan Stanley has invested 0% in Eleven Biotherapeutics, Inc. (NASDAQ:EBIO). Captrust Fincl Advsrs invested in 0% or 1,500 shares. Geode Cap Mgmt Ltd Liability Company invested in 0% or 56,222 shares. Royal Bank Of Canada stated it has 0% in Eleven Biotherapeutics, Inc. (NASDAQ:EBIO). Price T Rowe Associates Md invested in 52,700 shares. Commercial Bank Of Mellon Corp stated it has 0% in Eleven Biotherapeutics, Inc. (NASDAQ:EBIO). Vanguard Gp holds 0% of its portfolio in Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) for 206,450 shares. Panagora Asset Management holds 0% of its portfolio in Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) for 24,289 shares. Deutsche Bancorporation Ag owns 200 shares. 20,000 were reported by Fiduciary Company.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com